# ARQ 501 in Combination With Gemcitabine in Subjects With Pancreatic Cancer

> **NCT00102700** · PHASE2 · COMPLETED · sponsor: **ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)** · enrollment: 66 (—)

## Conditions studied

- Pancreatic Cancer
- Adenocarcinoma

## Interventions

- **DRUG:** ARQ 501 in combination with gemcitabine

## Key facts

- **NCT ID:** NCT00102700
- **Lead sponsor:** ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-01
- **Primary completion:** 2007-01
- **Final completion:** 2007-01
- **Target enrollment:** 66 (—)
- **Last updated:** 2009-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00102700

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00102700, "ARQ 501 in Combination With Gemcitabine in Subjects With Pancreatic Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00102700. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*